SlideShare uma empresa Scribd logo
1 de 48
Baixar para ler offline
Cochrane Present Tech
Cochrane Future Tech
Ida Sim, MD, PhD
University of California San Francisco
Open mHealth
September 17, 2013
• In 2003, estimate of 10-45,000 reviews needed to cover
existing evidence as of 2003
– projected Cochrane to hit 10,000 reviews between 2010 and 2015
Mallet and Clarke, EBM 2003(8):100-1
Total Protocols
Total Reviews
Total Updated Reviews1000th Cochrane review
5665 total reviews today
How can we better leverage technology
and knowledge to both help us prepare
systematic reviews more efficiently but
also deliver the outputs better to our
end-users?
Setting the Stage: PICOT
P opulation
I ntervention
C omparison
O utcome
T ime frame
Intervention
P
I Synthesized evidence, the "Cochrane Way"
C
O
T
(Target) Population
P Health care systems, clinicians
I Synthesized evidence, the Cochrane Way
C
O
T
Outcome
P Health care systems, clinicians
I Synthesized evidence, the Cochrane Way
C
O Population-level health outcomes & costs
T
Comparison
P Health care systems, clinicians
I Synthesized evidence, the Cochrane Way
C Eminence-based medicine
O Population-level health outcomes & costs
T
Time frame
P Health care systems, clinicians
I Synthesized evidence from the Cochrane Way
C Eminence-based medicine
O Population-level improvement in health, costs
T Too many yearsT
Setting the Present Stage
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many
Cochrane Future
P
I
C
O
T
Cochrane Way: Workflow
Technology for Pain Points
Setting the Future Stage
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P
I Cochrane Way
C
O
T
Additional Outcomes
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P
I Cochrane Way
C
O cost
T
Chronic Diseases Drive Cost
• 46% of morbidity and 59% mortality
worldwide due to chronic diseases1
• Health systems targeting chronic care
– 1/3 of deaths due to poor health behaviors
– need to engage patients in self-care
• Patients expect personalized medicine
– want evidence at the individual-patient level
WHO | Facts related to Chronic Disease
http://www.who.int/dietphysicalactivity/publications/facts/chronic/en/
Additional Outcomes and Population
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P add patients & families
I Cochrane Way
C
O add ind-level health
T
Time Frame
• Personal digital technologies will play large role in
chronic disease and transforming health
– 20,000 health apps on iTunes, 8,000 on Google Play
– technologies evolve rapidly
• US Institute of Medicine goal of a continuous
Learning Health System
Riley et al. Clinical and Translational Medicine 2013, 2:10
New Time Frame
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P add patients & families
I Cochrane Way
C
O add ind-level health
T continuous
New Comparison Intervention
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P add patients & families
I Cochrane Way
C Big Data
O add ind-level health
T continuous
Three Illustrative Projects
• N-of-1 studies for chronic pain
• Kaiser: Diabetes and depression management
• Health eHeart virtual cohort
PREEMPT Project
• Chronic Pain is highly prevalent (>100 million
Americans) and difficult to treat
• Few studies on comparative effectiveness of
analgesics, yielding only average population-level
estimates
R01-NR013938, PI R. Kravitz
50 people
100 people
oxycodone
Pain frequency, intensity
50 people
hydrocodone
population
Pain frequency, intensity
none of us are average
hydrocodone betteroxycodone better
which works better for you?
N-of-1 study design: within-subject crossover design
Kravitz, et al. Contemp Clin Trials 2009; 30:436-445
BPI
individual
pain intensity
You
pain intensity
oxycodone
hydrocodone
hydrocodone
oxycodone
oxycodone
hydrocodone
Cochrane Present Tech - Cochrane Future Tech
Cochrane Present Tech - Cochrane Future Tech
Cochrane Present Tech - Cochrane Future Tech
there you are!
hydrocodone betteroxycodone better
n = 1
(n 1).N
Zucker DR et al. J Clin Epidemiol. 2010;63(12):1312-23.
(n 1).N
Σ
flip direction of research
inference
population
Differences from Traditional Research
• Occurs in the course of clinical care
• Patient participation, addresses patient
questions
• Patient choice in outcomes measured
• Individual treatment effect
• Aggregate to population-level effect
S. California Kaiser Complete Care
Improving self-management of diabetes in patients with depression
Continuous Evaluation
• eHealth interventions will play a substantial role in
chronic care management and in shaping health
care systems
• Evaluations need to occur while they are being
designed, developed, and deployed.
Catwell and Sheikhl, PLoS Med 2009; 6(8):e1000126
Usability
Studies
Preliminary
effectiveness
User
Requirements
Pilot Field
Testing
Rigorous
effectiveness
Differences from Traditional Research
• Evidence is needed on intermediate non-
clinical outcomes (e.g., effective design
features) as well as end clinical effectiveness
• Many of these evaluations will not be
published in academic journals
Cochrane Present Tech - Cochrane Future Tech
• Enrolling 1,000,000 patients, capturing
– self report data: food intake, mood
– sensor data: weight, BP, activity
– social data: Facebook
– EHR data: including text mining for CV events
– biospecimens and CV tests for San Francisco area
patients
• Trades precise data on fewer patients for
messier data on 1000x more patients
– will be supplemented with targeted data collection
for specific studies
Future Cochrane Way?
Cochrane Present
P health systems, clinicians
I Cochrane Way
C eminence-based med
O pop-level health & cost
T too many years
Cochrane Future
P add patients & families
I Cochrane Way?
C Big Data
O add ind-level health
T continuous
"A good hockey player plays where the puck
is. A great hockey player plays where the puck
is going to be."
Wayne Gretsky, Edmonton Oilers
Where the Puck is Today
Studies in PDF Forest plots in PDF
Cochrane Way
Draws the most sound inference from the
totality of the available evidence
Where the Puck will be
Evidence =
study protocol + results
Synthesized evidence
continuous, multi-
modal, personal
data
more personalized
questions
large, less
controlled studies
individual-level
evidence
range of
acceptable rigor
continuous
release
schedule
Cochrane Way
Drawing the most sound inference from the totality of the available evidence
Build to Basic Principles
• Data sciences
• Operational
• Methodological
Data Sciences
• Beyond PDF reports of study results
– embrace data publishing
• publish protocols as computable models
• publish all results as open computable data
– text mining to extract meaning from prose
• No data silos: linked open data
• Describe the data: metadata and ontologies for
– study questions
– study design (Ontology of Clinical Research)
– systematic reviews (Cochrane Ontology)
Data Sciences Goal
• Capture open data in clearly described
computable form that can be re-purposed
for multiple needs today, and unknown
needs tomorrow
Operational
• Pursue hybrid semi-automated approaches
– seek out and work with the best designers of
human-computer interaction
• Support distributed, collaborative
knowledge work, tapping into crowds
Methods Needed
• Heterogeneity of treatment effect
• Continuous evaluation methods
• Large-scale assessment of biases and
confounders
• Better decision support for assessing biases
and confounders
• ...many more
The "Human Evidence Project"
+ + Methods
Data
Metadata
+
Most sound individual and population-level summary evidence for continuous
learning
Conclusion
• How to get from Cochrane Present to
Cochrane Future?
– new methods built on open data and ontologies
– design hybrid human-computer systems
• In new Big Data world, methodologically
sound but pragmatic, sustainable evidence
synthesis will be critical
• Need Cochrane now more than ever

Mais conteúdo relacionado

Mais procurados

Raising the bar: How NCCOR supports researchers
Raising the bar: How NCCOR supports researchersRaising the bar: How NCCOR supports researchers
Raising the bar: How NCCOR supports researchersNCCOR
 
Gai Moore, Sax Institute
Gai Moore, Sax InstituteGai Moore, Sax Institute
Gai Moore, Sax InstituteSax Institute
 
Fidye Westgarth, Agency for Clinical Innovation
Fidye Westgarth, Agency for Clinical InnovationFidye Westgarth, Agency for Clinical Innovation
Fidye Westgarth, Agency for Clinical InnovationSax Institute
 
Implementing Evidence Based Practice at BJU
Implementing Evidence Based Practice at BJUImplementing Evidence Based Practice at BJU
Implementing Evidence Based Practice at BJUJordan Kessler
 
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventSafety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventCanadian Patient Safety Institute
 
IRB Challenges QI vs Research
IRB Challenges   QI vs ResearchIRB Challenges   QI vs Research
IRB Challenges QI vs Researchmsschreiner
 
TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative TransCelerate
 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of careNuffield Trust
 
Cochrane reviews and guideline development: Is there anything new under the sun?
Cochrane reviews and guideline development: Is there anything new under the sun?Cochrane reviews and guideline development: Is there anything new under the sun?
Cochrane reviews and guideline development: Is there anything new under the sun?Health Informatics New Zealand
 
Ignite your medical funding opportunties eme
Ignite your medical funding opportunties emeIgnite your medical funding opportunties eme
Ignite your medical funding opportunties emeAlan Scrase
 
Joint working between the NHS and pharma
Joint working between the NHS and pharmaJoint working between the NHS and pharma
Joint working between the NHS and pharmaPM Society
 
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...Covance
 
The vision for the Wessex AHSN
The vision for the Wessex AHSNThe vision for the Wessex AHSN
The vision for the Wessex AHSNPM Society
 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeNuffield Trust
 
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...Carl Walker
 
What's new in the uk nsc
What's new in the uk nscWhat's new in the uk nsc
What's new in the uk nscPHEScreening
 
Ukes process tracing presentation
Ukes process tracing presentationUkes process tracing presentation
Ukes process tracing presentationItad Ltd
 

Mais procurados (20)

Raising the bar: How NCCOR supports researchers
Raising the bar: How NCCOR supports researchersRaising the bar: How NCCOR supports researchers
Raising the bar: How NCCOR supports researchers
 
Gai Moore, Sax Institute
Gai Moore, Sax InstituteGai Moore, Sax Institute
Gai Moore, Sax Institute
 
Fidye Westgarth, Agency for Clinical Innovation
Fidye Westgarth, Agency for Clinical InnovationFidye Westgarth, Agency for Clinical Innovation
Fidye Westgarth, Agency for Clinical Innovation
 
Implementing Evidence Based Practice at BJU
Implementing Evidence Based Practice at BJUImplementing Evidence Based Practice at BJU
Implementing Evidence Based Practice at BJU
 
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec EventSafety, Sleuthing and Students: A Novel Collaborative MedRec Event
Safety, Sleuthing and Students: A Novel Collaborative MedRec Event
 
IRB Challenges QI vs Research
IRB Challenges   QI vs ResearchIRB Challenges   QI vs Research
IRB Challenges QI vs Research
 
TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative TransCelerate Overview - Patient Experience Initiative
TransCelerate Overview - Patient Experience Initiative
 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of care
 
Cochrane reviews and guideline development: Is there anything new under the sun?
Cochrane reviews and guideline development: Is there anything new under the sun?Cochrane reviews and guideline development: Is there anything new under the sun?
Cochrane reviews and guideline development: Is there anything new under the sun?
 
Ignite your medical funding opportunties eme
Ignite your medical funding opportunties emeIgnite your medical funding opportunties eme
Ignite your medical funding opportunties eme
 
Innovative change strategies for patient safety (1 of 2)
Innovative change strategies for patient safety (1 of 2)Innovative change strategies for patient safety (1 of 2)
Innovative change strategies for patient safety (1 of 2)
 
Joint working between the NHS and pharma
Joint working between the NHS and pharmaJoint working between the NHS and pharma
Joint working between the NHS and pharma
 
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...
Improving Study Start Up and Recruitment for a Drug-Device Clinical Trial Cas...
 
The vision for the Wessex AHSN
The vision for the Wessex AHSNThe vision for the Wessex AHSN
The vision for the Wessex AHSN
 
National Priorities and Research Agenda
National Priorities and Research AgendaNational Priorities and Research Agenda
National Priorities and Research Agenda
 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers Programme
 
Health research priorities 2015
Health research priorities 2015Health research priorities 2015
Health research priorities 2015
 
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...
National Quality Improvement & Clinical Audit Network (NQICAN) Annual Report ...
 
What's new in the uk nsc
What's new in the uk nscWhat's new in the uk nsc
What's new in the uk nsc
 
Ukes process tracing presentation
Ukes process tracing presentationUkes process tracing presentation
Ukes process tracing presentation
 

Destaque

Impact of translations on access to Cochrane reviews
Impact of translations on access to Cochrane reviewsImpact of translations on access to Cochrane reviews
Impact of translations on access to Cochrane reviewsCochrane.Collaboration
 
Beyond the PDF + linked data and other futuristic stuff
Beyond the PDF + linked data and other futuristic stuffBeyond the PDF + linked data and other futuristic stuff
Beyond the PDF + linked data and other futuristic stuffCochrane.Collaboration
 
Text mining, machine learning, NLP and all that (in 10 minutes)
Text mining, machine learning, NLP and all that (in 10 minutes)Text mining, machine learning, NLP and all that (in 10 minutes)
Text mining, machine learning, NLP and all that (in 10 minutes)Cochrane.Collaboration
 
Tools and interfaces for systematic reviews
Tools and interfaces for systematic reviewsTools and interfaces for systematic reviews
Tools and interfaces for systematic reviewsCochrane.Collaboration
 
Future of the article C Mavergames March 2013
Future of the article C Mavergames March 2013Future of the article C Mavergames March 2013
Future of the article C Mavergames March 2013Cochrane.Collaboration
 

Destaque (7)

Impact of translations on access to Cochrane reviews
Impact of translations on access to Cochrane reviewsImpact of translations on access to Cochrane reviews
Impact of translations on access to Cochrane reviews
 
Cochrane Tech: The Wider Context
Cochrane Tech: The Wider ContextCochrane Tech: The Wider Context
Cochrane Tech: The Wider Context
 
Beyond the PDF + linked data and other futuristic stuff
Beyond the PDF + linked data and other futuristic stuffBeyond the PDF + linked data and other futuristic stuff
Beyond the PDF + linked data and other futuristic stuff
 
Text mining, machine learning, NLP and all that (in 10 minutes)
Text mining, machine learning, NLP and all that (in 10 minutes)Text mining, machine learning, NLP and all that (in 10 minutes)
Text mining, machine learning, NLP and all that (in 10 minutes)
 
Tools and interfaces for systematic reviews
Tools and interfaces for systematic reviewsTools and interfaces for systematic reviews
Tools and interfaces for systematic reviews
 
Future of the article C Mavergames March 2013
Future of the article C Mavergames March 2013Future of the article C Mavergames March 2013
Future of the article C Mavergames March 2013
 
Crowdsourcing and Cochrane
Crowdsourcing and CochraneCrowdsourcing and Cochrane
Crowdsourcing and Cochrane
 

Semelhante a Cochrane Present Tech - Cochrane Future Tech

REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15Zoe Mitchell
 
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...'Demystifying Knowledge Transfer- an introduction to Implementation Science M...
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...NEQOS
 
Methods for Observational Comparative Effectiveness Research on Healthcare De...
Methods for Observational Comparative Effectiveness Research on Healthcare De...Methods for Observational Comparative Effectiveness Research on Healthcare De...
Methods for Observational Comparative Effectiveness Research on Healthcare De...Marion Sills
 
College Writing II Synthesis Essay Assignment Summer Semester 2017.docx
College Writing II Synthesis Essay Assignment Summer Semester 2017.docxCollege Writing II Synthesis Essay Assignment Summer Semester 2017.docx
College Writing II Synthesis Essay Assignment Summer Semester 2017.docxclarebernice
 
From Research to Practice - New Models for Data-sharing and Collaboration to ...
From Research to Practice - New Models for Data-sharing and Collaboration to ...From Research to Practice - New Models for Data-sharing and Collaboration to ...
From Research to Practice - New Models for Data-sharing and Collaboration to ...Health Data Consortium
 
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...European School of Oncology
 
Evidence based practice power
Evidence based practice powerEvidence based practice power
Evidence based practice powerMahmoud Shaqria
 
EVIDENCE BASED.ppt
EVIDENCE BASED.pptEVIDENCE BASED.ppt
EVIDENCE BASED.pptmalti19
 
Embi cri yir-2017-final
Embi cri yir-2017-finalEmbi cri yir-2017-final
Embi cri yir-2017-finalPeter Embi
 
Evidence Based Practice -By Ritika Soni
Evidence Based Practice -By Ritika SoniEvidence Based Practice -By Ritika Soni
Evidence Based Practice -By Ritika SoniShimla
 
Computer System Validation - privacy zones, eSource and EHR data in clinical ...
Computer System Validation - privacy zones, eSource and EHR data in clinical ...Computer System Validation - privacy zones, eSource and EHR data in clinical ...
Computer System Validation - privacy zones, eSource and EHR data in clinical ...Wolfgang Kuchinke
 
Computer System Validation with privacy zones, e-source and clinical trials b...
Computer System Validation with privacy zones, e-source and clinical trials b...Computer System Validation with privacy zones, e-source and clinical trials b...
Computer System Validation with privacy zones, e-source and clinical trials b...Wolfgang Kuchinke
 
Computer validation of e-source and EHR in clinical trials-Kuchinke
Computer validation of e-source and EHR in clinical trials-KuchinkeComputer validation of e-source and EHR in clinical trials-Kuchinke
Computer validation of e-source and EHR in clinical trials-KuchinkeWolfgang Kuchinke
 
Volmink Dfidsept2009jvfinal
Volmink Dfidsept2009jvfinalVolmink Dfidsept2009jvfinal
Volmink Dfidsept2009jvfinalCRUOnline
 
Embi cri review-2013-final
Embi cri review-2013-finalEmbi cri review-2013-final
Embi cri review-2013-finalPeter Embi
 
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...Wimmics seminar--drug interaction knowledge base, micropublication, open anno...
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...jodischneider
 

Semelhante a Cochrane Present Tech - Cochrane Future Tech (20)

REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15
 
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...'Demystifying Knowledge Transfer- an introduction to Implementation Science M...
'Demystifying Knowledge Transfer- an introduction to Implementation Science M...
 
Methods for Observational Comparative Effectiveness Research on Healthcare De...
Methods for Observational Comparative Effectiveness Research on Healthcare De...Methods for Observational Comparative Effectiveness Research on Healthcare De...
Methods for Observational Comparative Effectiveness Research on Healthcare De...
 
Evidence Based Medicine
Evidence Based Medicine Evidence Based Medicine
Evidence Based Medicine
 
PCORI: Engaging Patients in Clinical Trials & Outcomes Research
PCORI: Engaging Patients in Clinical Trials & Outcomes ResearchPCORI: Engaging Patients in Clinical Trials & Outcomes Research
PCORI: Engaging Patients in Clinical Trials & Outcomes Research
 
College Writing II Synthesis Essay Assignment Summer Semester 2017.docx
College Writing II Synthesis Essay Assignment Summer Semester 2017.docxCollege Writing II Synthesis Essay Assignment Summer Semester 2017.docx
College Writing II Synthesis Essay Assignment Summer Semester 2017.docx
 
From Research to Practice: New Models for Data-sharing and Collaboration to I...
From Research to Practice: New Models for Data-sharing and Collaboration to I...From Research to Practice: New Models for Data-sharing and Collaboration to I...
From Research to Practice: New Models for Data-sharing and Collaboration to I...
 
From Research to Practice - New Models for Data-sharing and Collaboration to ...
From Research to Practice - New Models for Data-sharing and Collaboration to ...From Research to Practice - New Models for Data-sharing and Collaboration to ...
From Research to Practice - New Models for Data-sharing and Collaboration to ...
 
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...
NY Prostate Cancer Conference - A. Pusic - Session 6: Quality of life instrum...
 
Evidence based practice power
Evidence based practice powerEvidence based practice power
Evidence based practice power
 
EVIDENCE BASED.ppt
EVIDENCE BASED.pptEVIDENCE BASED.ppt
EVIDENCE BASED.ppt
 
Big Data and Stratified Medicine
Big Data and Stratified MedicineBig Data and Stratified Medicine
Big Data and Stratified Medicine
 
Embi cri yir-2017-final
Embi cri yir-2017-finalEmbi cri yir-2017-final
Embi cri yir-2017-final
 
Evidence Based Practice -By Ritika Soni
Evidence Based Practice -By Ritika SoniEvidence Based Practice -By Ritika Soni
Evidence Based Practice -By Ritika Soni
 
Computer System Validation - privacy zones, eSource and EHR data in clinical ...
Computer System Validation - privacy zones, eSource and EHR data in clinical ...Computer System Validation - privacy zones, eSource and EHR data in clinical ...
Computer System Validation - privacy zones, eSource and EHR data in clinical ...
 
Computer System Validation with privacy zones, e-source and clinical trials b...
Computer System Validation with privacy zones, e-source and clinical trials b...Computer System Validation with privacy zones, e-source and clinical trials b...
Computer System Validation with privacy zones, e-source and clinical trials b...
 
Computer validation of e-source and EHR in clinical trials-Kuchinke
Computer validation of e-source and EHR in clinical trials-KuchinkeComputer validation of e-source and EHR in clinical trials-Kuchinke
Computer validation of e-source and EHR in clinical trials-Kuchinke
 
Volmink Dfidsept2009jvfinal
Volmink Dfidsept2009jvfinalVolmink Dfidsept2009jvfinal
Volmink Dfidsept2009jvfinal
 
Embi cri review-2013-final
Embi cri review-2013-finalEmbi cri review-2013-final
Embi cri review-2013-final
 
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...Wimmics seminar--drug interaction knowledge base, micropublication, open anno...
Wimmics seminar--drug interaction knowledge base, micropublication, open anno...
 

Mais de Cochrane.Collaboration

2. Opening of the Austrian Cochrane Branch - Marcus Muellner
2. Opening of the Austrian Cochrane Branch - Marcus Muellner2. Opening of the Austrian Cochrane Branch - Marcus Muellner
2. Opening of the Austrian Cochrane Branch - Marcus MuellnerCochrane.Collaboration
 
3. Opening of the Austrian Cochrane Branch - Ruth Gilbert
3. Opening of the Austrian Cochrane Branch - Ruth Gilbert3. Opening of the Austrian Cochrane Branch - Ruth Gilbert
3. Opening of the Austrian Cochrane Branch - Ruth GilbertCochrane.Collaboration
 
1. Opening of the Austrian Cochrane Branch - Iain Chalmers
1. Opening of the Austrian Cochrane Branch - Iain Chalmers1. Opening of the Austrian Cochrane Branch - Iain Chalmers
1. Opening of the Austrian Cochrane Branch - Iain ChalmersCochrane.Collaboration
 
5. Opening of the Austrian Cochrane Branch - Gerd Antes
5. Opening of the Austrian Cochrane Branch - Gerd Antes5. Opening of the Austrian Cochrane Branch - Gerd Antes
5. Opening of the Austrian Cochrane Branch - Gerd AntesCochrane.Collaboration
 
4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier
4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier
4. Opening of the Austrian Cochrane Branch - Wolfgang GaissmaierCochrane.Collaboration
 
Cochrane Database of Systematic Reviews: Indexing, Citations & Bibliometrics
Cochrane Database of Systematic Reviews: Indexing, Citations & BibliometricsCochrane Database of Systematic Reviews: Indexing, Citations & Bibliometrics
Cochrane Database of Systematic Reviews: Indexing, Citations & BibliometricsCochrane.Collaboration
 
Cochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane.Collaboration
 
Cochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane.Collaboration
 
Globalizing clinical and health care policy processes
Globalizing clinical and health care policy processesGlobalizing clinical and health care policy processes
Globalizing clinical and health care policy processesCochrane.Collaboration
 
Connecting patients to the best-evidence through technology: An effective sol...
Connecting patients to the best-evidence through technology: An effective sol...Connecting patients to the best-evidence through technology: An effective sol...
Connecting patients to the best-evidence through technology: An effective sol...Cochrane.Collaboration
 
Globalizing management of high quality evidence for health care
Globalizing management of high quality evidence for health careGlobalizing management of high quality evidence for health care
Globalizing management of high quality evidence for health careCochrane.Collaboration
 
Globalizing clinical and health care policy processes
Globalizing clinical and health care policy processesGlobalizing clinical and health care policy processes
Globalizing clinical and health care policy processesCochrane.Collaboration
 
Globalizing the application of evidence-based policy and practices: the Phili...
Globalizing the application of evidence-based policy and practices: the Phili...Globalizing the application of evidence-based policy and practices: the Phili...
Globalizing the application of evidence-based policy and practices: the Phili...Cochrane.Collaboration
 
Balancing benefits and risks of drug treatment
Balancing benefits and risks of drug treatmentBalancing benefits and risks of drug treatment
Balancing benefits and risks of drug treatmentCochrane.Collaboration
 
Let’s celebrate the death of the medical journal
Let’s celebrate the death of the medical journalLet’s celebrate the death of the medical journal
Let’s celebrate the death of the medical journalCochrane.Collaboration
 
Evidence to policy to action – the view of a decision maker
Evidence to policy to action – the view of a decision makerEvidence to policy to action – the view of a decision maker
Evidence to policy to action – the view of a decision makerCochrane.Collaboration
 
Corporate responsibility for the right to health
Corporate responsibility for the right to healthCorporate responsibility for the right to health
Corporate responsibility for the right to healthCochrane.Collaboration
 
Perspectives on Cochrane Reviews from a User in the U.S.
Perspectives on Cochrane Reviews from a User in the U.S.Perspectives on Cochrane Reviews from a User in the U.S.
Perspectives on Cochrane Reviews from a User in the U.S.Cochrane.Collaboration
 
Organisational development within the Cochrane Collaboration: Establishing a ...
Organisational development within the Cochrane Collaboration: Establishing a ...Organisational development within the Cochrane Collaboration: Establishing a ...
Organisational development within the Cochrane Collaboration: Establishing a ...Cochrane.Collaboration
 

Mais de Cochrane.Collaboration (20)

2. Opening of the Austrian Cochrane Branch - Marcus Muellner
2. Opening of the Austrian Cochrane Branch - Marcus Muellner2. Opening of the Austrian Cochrane Branch - Marcus Muellner
2. Opening of the Austrian Cochrane Branch - Marcus Muellner
 
3. Opening of the Austrian Cochrane Branch - Ruth Gilbert
3. Opening of the Austrian Cochrane Branch - Ruth Gilbert3. Opening of the Austrian Cochrane Branch - Ruth Gilbert
3. Opening of the Austrian Cochrane Branch - Ruth Gilbert
 
1. Opening of the Austrian Cochrane Branch - Iain Chalmers
1. Opening of the Austrian Cochrane Branch - Iain Chalmers1. Opening of the Austrian Cochrane Branch - Iain Chalmers
1. Opening of the Austrian Cochrane Branch - Iain Chalmers
 
5. Opening of the Austrian Cochrane Branch - Gerd Antes
5. Opening of the Austrian Cochrane Branch - Gerd Antes5. Opening of the Austrian Cochrane Branch - Gerd Antes
5. Opening of the Austrian Cochrane Branch - Gerd Antes
 
4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier
4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier
4. Opening of the Austrian Cochrane Branch - Wolfgang Gaissmaier
 
Cochrane Database of Systematic Reviews: Indexing, Citations & Bibliometrics
Cochrane Database of Systematic Reviews: Indexing, Citations & BibliometricsCochrane Database of Systematic Reviews: Indexing, Citations & Bibliometrics
Cochrane Database of Systematic Reviews: Indexing, Citations & Bibliometrics
 
Cochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies Consultation
 
Cochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies ConsultationCochrane Collaboration - Register of Studies Consultation
Cochrane Collaboration - Register of Studies Consultation
 
Globalizing clinical and health care policy processes
Globalizing clinical and health care policy processesGlobalizing clinical and health care policy processes
Globalizing clinical and health care policy processes
 
Connecting patients to the best-evidence through technology: An effective sol...
Connecting patients to the best-evidence through technology: An effective sol...Connecting patients to the best-evidence through technology: An effective sol...
Connecting patients to the best-evidence through technology: An effective sol...
 
Globalizing management of high quality evidence for health care
Globalizing management of high quality evidence for health careGlobalizing management of high quality evidence for health care
Globalizing management of high quality evidence for health care
 
Evidence in the era of globalization
Evidence in the era of globalizationEvidence in the era of globalization
Evidence in the era of globalization
 
Globalizing clinical and health care policy processes
Globalizing clinical and health care policy processesGlobalizing clinical and health care policy processes
Globalizing clinical and health care policy processes
 
Globalizing the application of evidence-based policy and practices: the Phili...
Globalizing the application of evidence-based policy and practices: the Phili...Globalizing the application of evidence-based policy and practices: the Phili...
Globalizing the application of evidence-based policy and practices: the Phili...
 
Balancing benefits and risks of drug treatment
Balancing benefits and risks of drug treatmentBalancing benefits and risks of drug treatment
Balancing benefits and risks of drug treatment
 
Let’s celebrate the death of the medical journal
Let’s celebrate the death of the medical journalLet’s celebrate the death of the medical journal
Let’s celebrate the death of the medical journal
 
Evidence to policy to action – the view of a decision maker
Evidence to policy to action – the view of a decision makerEvidence to policy to action – the view of a decision maker
Evidence to policy to action – the view of a decision maker
 
Corporate responsibility for the right to health
Corporate responsibility for the right to healthCorporate responsibility for the right to health
Corporate responsibility for the right to health
 
Perspectives on Cochrane Reviews from a User in the U.S.
Perspectives on Cochrane Reviews from a User in the U.S.Perspectives on Cochrane Reviews from a User in the U.S.
Perspectives on Cochrane Reviews from a User in the U.S.
 
Organisational development within the Cochrane Collaboration: Establishing a ...
Organisational development within the Cochrane Collaboration: Establishing a ...Organisational development within the Cochrane Collaboration: Establishing a ...
Organisational development within the Cochrane Collaboration: Establishing a ...
 

Último

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 

Último (20)

Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 

Cochrane Present Tech - Cochrane Future Tech

  • 1. Cochrane Present Tech Cochrane Future Tech Ida Sim, MD, PhD University of California San Francisco Open mHealth September 17, 2013
  • 2. • In 2003, estimate of 10-45,000 reviews needed to cover existing evidence as of 2003 – projected Cochrane to hit 10,000 reviews between 2010 and 2015 Mallet and Clarke, EBM 2003(8):100-1 Total Protocols Total Reviews Total Updated Reviews1000th Cochrane review 5665 total reviews today
  • 3. How can we better leverage technology and knowledge to both help us prepare systematic reviews more efficiently but also deliver the outputs better to our end-users?
  • 4. Setting the Stage: PICOT P opulation I ntervention C omparison O utcome T ime frame
  • 5. Intervention P I Synthesized evidence, the "Cochrane Way" C O T
  • 6. (Target) Population P Health care systems, clinicians I Synthesized evidence, the Cochrane Way C O T
  • 7. Outcome P Health care systems, clinicians I Synthesized evidence, the Cochrane Way C O Population-level health outcomes & costs T
  • 8. Comparison P Health care systems, clinicians I Synthesized evidence, the Cochrane Way C Eminence-based medicine O Population-level health outcomes & costs T
  • 9. Time frame P Health care systems, clinicians I Synthesized evidence from the Cochrane Way C Eminence-based medicine O Population-level improvement in health, costs T Too many yearsT
  • 10. Setting the Present Stage Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many Cochrane Future P I C O T
  • 13. Setting the Future Stage Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P I Cochrane Way C O T
  • 14. Additional Outcomes Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P I Cochrane Way C O cost T
  • 15. Chronic Diseases Drive Cost • 46% of morbidity and 59% mortality worldwide due to chronic diseases1 • Health systems targeting chronic care – 1/3 of deaths due to poor health behaviors – need to engage patients in self-care • Patients expect personalized medicine – want evidence at the individual-patient level WHO | Facts related to Chronic Disease http://www.who.int/dietphysicalactivity/publications/facts/chronic/en/
  • 16. Additional Outcomes and Population Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P add patients & families I Cochrane Way C O add ind-level health T
  • 17. Time Frame • Personal digital technologies will play large role in chronic disease and transforming health – 20,000 health apps on iTunes, 8,000 on Google Play – technologies evolve rapidly • US Institute of Medicine goal of a continuous Learning Health System Riley et al. Clinical and Translational Medicine 2013, 2:10
  • 18. New Time Frame Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P add patients & families I Cochrane Way C O add ind-level health T continuous
  • 19. New Comparison Intervention Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P add patients & families I Cochrane Way C Big Data O add ind-level health T continuous
  • 20. Three Illustrative Projects • N-of-1 studies for chronic pain • Kaiser: Diabetes and depression management • Health eHeart virtual cohort
  • 21. PREEMPT Project • Chronic Pain is highly prevalent (>100 million Americans) and difficult to treat • Few studies on comparative effectiveness of analgesics, yielding only average population-level estimates R01-NR013938, PI R. Kravitz 50 people 100 people oxycodone Pain frequency, intensity 50 people hydrocodone population Pain frequency, intensity
  • 22. none of us are average hydrocodone betteroxycodone better
  • 23. which works better for you? N-of-1 study design: within-subject crossover design Kravitz, et al. Contemp Clin Trials 2009; 30:436-445 BPI individual pain intensity You pain intensity oxycodone hydrocodone hydrocodone oxycodone oxycodone hydrocodone
  • 27. there you are! hydrocodone betteroxycodone better
  • 28. n = 1
  • 30. Zucker DR et al. J Clin Epidemiol. 2010;63(12):1312-23. (n 1).N Σ
  • 31. flip direction of research inference population
  • 32. Differences from Traditional Research • Occurs in the course of clinical care • Patient participation, addresses patient questions • Patient choice in outcomes measured • Individual treatment effect • Aggregate to population-level effect
  • 33. S. California Kaiser Complete Care Improving self-management of diabetes in patients with depression
  • 34. Continuous Evaluation • eHealth interventions will play a substantial role in chronic care management and in shaping health care systems • Evaluations need to occur while they are being designed, developed, and deployed. Catwell and Sheikhl, PLoS Med 2009; 6(8):e1000126 Usability Studies Preliminary effectiveness User Requirements Pilot Field Testing Rigorous effectiveness
  • 35. Differences from Traditional Research • Evidence is needed on intermediate non- clinical outcomes (e.g., effective design features) as well as end clinical effectiveness • Many of these evaluations will not be published in academic journals
  • 37. • Enrolling 1,000,000 patients, capturing – self report data: food intake, mood – sensor data: weight, BP, activity – social data: Facebook – EHR data: including text mining for CV events – biospecimens and CV tests for San Francisco area patients • Trades precise data on fewer patients for messier data on 1000x more patients – will be supplemented with targeted data collection for specific studies
  • 38. Future Cochrane Way? Cochrane Present P health systems, clinicians I Cochrane Way C eminence-based med O pop-level health & cost T too many years Cochrane Future P add patients & families I Cochrane Way? C Big Data O add ind-level health T continuous
  • 39. "A good hockey player plays where the puck is. A great hockey player plays where the puck is going to be." Wayne Gretsky, Edmonton Oilers
  • 40. Where the Puck is Today Studies in PDF Forest plots in PDF Cochrane Way Draws the most sound inference from the totality of the available evidence
  • 41. Where the Puck will be Evidence = study protocol + results Synthesized evidence continuous, multi- modal, personal data more personalized questions large, less controlled studies individual-level evidence range of acceptable rigor continuous release schedule Cochrane Way Drawing the most sound inference from the totality of the available evidence
  • 42. Build to Basic Principles • Data sciences • Operational • Methodological
  • 43. Data Sciences • Beyond PDF reports of study results – embrace data publishing • publish protocols as computable models • publish all results as open computable data – text mining to extract meaning from prose • No data silos: linked open data • Describe the data: metadata and ontologies for – study questions – study design (Ontology of Clinical Research) – systematic reviews (Cochrane Ontology)
  • 44. Data Sciences Goal • Capture open data in clearly described computable form that can be re-purposed for multiple needs today, and unknown needs tomorrow
  • 45. Operational • Pursue hybrid semi-automated approaches – seek out and work with the best designers of human-computer interaction • Support distributed, collaborative knowledge work, tapping into crowds
  • 46. Methods Needed • Heterogeneity of treatment effect • Continuous evaluation methods • Large-scale assessment of biases and confounders • Better decision support for assessing biases and confounders • ...many more
  • 47. The "Human Evidence Project" + + Methods Data Metadata + Most sound individual and population-level summary evidence for continuous learning
  • 48. Conclusion • How to get from Cochrane Present to Cochrane Future? – new methods built on open data and ontologies – design hybrid human-computer systems • In new Big Data world, methodologically sound but pragmatic, sustainable evidence synthesis will be critical • Need Cochrane now more than ever

Notas do Editor

  1. It's an honor to be here, at Cochrane's 20thanniversary. The first 1000 Cochrane reviews took 8 years, until 2001, to be completed. 20 years on, there are now 5665 total reviews. On the one hand, this is outstanding progress, but on the other, it's not nearly enough. In 2003, Mallet and Clarke estimated that at least 10,000 systematic reviewers were needed just to cover the existing evidence at that time, in 2003. They projected that Cochrane would produce these 10,000 reviews sometime between 2010-2015. But being only about half way there, that projection is unlikely to be met. And of course, now many thousands more systematic reviews are needed to cover the tens of thousands of additional RCTs that have been published since 2003. It isn't news to you this mismatch between demand and production of Cochrane reviews, nor is it news to you that the problem is getting worse. The hope is that technology will come to the rescue. ~~~~~~~~~~http://www.cochrane.org/cochrane-reviews/cochrane-database-systematic-reviews-numbershttp://www.thecochranelibrary.com/view/0/AboutTheCochraneLibrary.html
  2. The question for today's conference is …I'd like to consider this question in 2 parts.One is what we can do with technology in the next 1-2 years, Cochrane Present Tech; and the 2nd part is Cochrane Future Tech for 3-5 years out.
  3. Let's set the stage. A good practitioner of EBM always starts with a clear question. Considering Cochrane as an intervention, what is Cochrane's PICOT question?
  4. First, the intervention is synthesized evidence generated by the Cochrane Way, which we'll say more about later.
  5. Cochrane evidence is primarily targeted to health care systems, and clinicians.
  6. to improve population-level health outcomes and cost.
  7. The main comparison to Evidence-Based Medicine the Cochrane Way is Eminence-basedmedicine, which is self-descriptive.
  8. And thetimeframe? You've heard that it takes an average of 17 years for clinical trial results to be put into practice. Whatever the delay is for primary studies, the delay is even more for systematic reviews. I couldn't find any studies on the time it takes for Cochrane reviews to impact care, but it's probably "too many years."
  9. So this is the PICOT question for Cochrane Present. Cochrane Future is coming fast, but let's leave that aside right now, and look first at how technology can help the Cochrane in the next 1-2 years.
  10. Here's a high level workflow of systematic reviewing, with a Cochrane Way to doing each of these steps. I know you're all very familiar with this so I'll just highlight a few points. First, there is a lot of iteration in the early steps, where a question is initially framed then revised in response to the details of the studies that are available. Second, there's a loop for updating and revising the reviews. Finally, that Dissemination and Implementation is often after and divorced from the process of conducting the reviews.
  11. In the lightning talks later this morning, we will be hearing about technology being used for specific pain points in this workflow, like citation screening, supporting collaboration and supporting Dissemination and Implementation. There are many other technology projects we could discuss for other pain points here, but the elephant in the room is that things are changing, and you might be wondering how we should solve today's pain points in a way that will remain relevant for tomorrow.
  12. Because the PICOT question for Cochrane Future will be quite different from today's. The interventionwill still be the Cochrane Way, which we will have to re-imagine.
  13. For outcomes, cost is becoming an ever bigger driver.
  14. This has implications for the type of evidence we want. The biggest driver of health care costs is chronic diseases. To reduce costs, health care systems are going to where the money is, and are focusing on chronic care. And because by definition chronic disease is 24/7 in patient's daily lives, and 1/3 of deaths are due to poor health behaviors that only patients can change, health care systems need to engage patients in their self-care.Nowadays, patients are savvy consumers and expect personalized medicine, and they will want evidence at the individual-patient level to help them self-manage.http://buyersguide.macrumors.com/
  15. There will thus be more demand for "personalized evidence," from patients and their families, for individual-level estimates of treatment effect.
  16. As health care systems increasingly focus on self-care and improving personal behaviors, personal digital technologies like apps and sensors will play a large role in transforming health care. These technologies evolve rapidly, with a "metabolic rate" that is like nothing we've seen before. Here's a figure from a very nice paper by Riley and colleagues showing that a typical RCT published in 2012 was probably designed and submitted for funding in 2006, when the Wii came out, and it spans the introduction of the iPhone, Android, iPad and Siri by the time it's analyzed and published.The pace of traditional research is simply too slow, and is also not compatible with the US Institute of Medicine's goal of a continuous learning health system, where care and research drive each other in tight iterative feedback loops. http://www.imedicalapps.com/2013/07/apple-android-medical-app/
  17. So the time frame for Cochrane Future is going from Too many years to continuous.
  18. And finally, the comparison intervention for Cochrane won't be Eminence-based medicine anymore, but Big Data. The buzz around Big Data seems to take correlation for causation, that simply by having massive amounts of EHR data together in the cloud, we can somehow get all our answers. Clinical trials, in contrast seem so much less modern, yet we know that careful methodology is more not less important for interpreting Big Data and especially for synthesizing inferences drawn from Big Data.
  19. I'd like to illustrate these dimensions of change through three projects I'm working on.
  20. The first is the PREEMPT Project which addresses the highly prevalent problem of chronic pain. This is a frustrating problem to treat because there are few studies on which pain meds are better, and the studies only yield population-level estimates, which is what we get from standard RCTs.
  21. In our project, a chronicpatient sits down with their doctor to select the pain regimens they want to compare, for example…
  22. define the length of time on each treatment – 2 weeks -- and the number of times they'll take each treatment – 3 times. This would be a 6-week n-of-1 trial.
  23. and they can customize the outcomes to what is most relevant to them. For example, opiates can dull our thinking and concentration in different ways for different patients. In this project, we allow patients to select the cognitive symptom that is most relevant to them, like . Immediately after setup, the patient can download the Trialist app onto his/her cell phone which guides them through their custom n-of-1 study, 6 weeks in this case.Allowing patients to choose their outcomes is patient-centered, keeps them engaged in continuing the study, and gives them evidence that THEY want and will find useful. Of course, only some clinical questions can be answered with n-of-1 studies but this is a valuable study design that is much more feasible now with new technology.
  24. n-of-1 studies can be even more powerful if we go from just one study
  25. to many n-of-1 studies, so that more people can get individual estimates of treatment effect,
  26. to summing the evidence from these studies for example using Zucker'sBayesian meta-analysis methods
  27. So n-of-1studies illustrate some differences from the traditional RCT. First, it is conducted as an integral part of clinical care. Patients are full partners, participating in defining the question, choosing the treatments to compare, and the outcomes measured. The results are estimates of individual-level effects, which can be aggregated to yield estimates of population-level effects.
  28. My second example is a project that Open mHealth is doing with Kaiser San Diego to improve the self-management of diabetes in patients with depression. It's a very complex intervention:Patients track their glucose, BP, weight and activity using various wearable sensors. They self-report depression and other symptoms on the cell phone, behavioral and social metrics are collected in an app called Ginger.io, a company called FrameHealth delivers incentives and motivations based on a psychological profiling of the patient. All this data is put together with EHR data to support self-care, family and friends care, and the Kaiser care team.
  29. These kinds of multi-modal interventions are going to become more common for managing chronic diseases and indeed for shaping the entire health care system. We desperately need evidence of what works and what doesn't, but these complex interventions are made up of many moving parts that should be evaluated as they are being designed, developed, and deployed. For example, did you know that Google runs hundreds of little RCTs every day on little tweaks to their search algorithm and interfaces? They randomize you to getting this or that type of result or a font or a placement of an ad, and after oh several hours, they've accrued several hundred thousand subjects and a result that they use immediately to keep improving their search site. eHealth interventions need to adopt this agile development and evaluation approach. This type of evidence is valuable to synthesize and share to improve the eventual effectiveness of eHealth. The analogy is to drug development. If we only shared Phase 3 studies of drugs, we would be missing out on very useful evidence earlier in the drug development pipeline, about toxicity and pharmacokinetics for instance. It just that the Phase 1 and 2 studies for eHealth will be small, fast, and very iterative.
  30. The differences in this example are
  31. My final example is the Health eHeart project, which you can think of as a "virtual Framingham" cohort study. We are aiming to enroll 1,000,000 patients worldwide who have or are interested in cardiovascular disease.
  32. We are capturing from these patients: What's different about this study is that we're trading carefully obtained, precisely phenotyped data on fewerpatients for messier data on orders of magnitude more patients. Clearly, this approach opens up exciting possibilities for research but also introduces many methodological concerns.
  33. Given all these changes, what will the future Cochrane look like? Because we're in Canada, and because I'm Canadian and from Edmonton,
  34. I have to quote Wayne Gretsky:
  35. Grossly simplified, this is where the puck is today. We have PDFsreporting on studies completed years ago, and Cochrane converts that to Forest plots in PDF, by drawing the most sound inference from the totality of the available evidence.
  36. This is where the puck willbe in 3-5 years, The challenge still is to draw the most sound inference from the totality of available evidence, but both the input and the outputs will be different, as shown by our examples. like in n-of-1, the results will be more personalized, and the users will want synthesized evidence FOR THEM INDIVIDUALLYlike the Kaiser project, data will be large, disparate, very personal data, generating clinical and non-clinical evidence with varying degrees rigor. Evidence synthesis will need to accommodate this range of rigor, we can't just stick with standard RCTs, and to help users understand and adjust for weaknesses.like HeH, large less precisely controlled studies that trade numbers for precision, drawing in many cases on the promise of Big Data. And patients and the health care system will want evidence on a continuous release schedule. The Cochrane Way will have to change to meet these new expectations. It's not clear how, but I think there are some basic principles that Cochrane should build to on the way there.
  37. These basic principles are data science related, operational and methodological.
  38. On the data front, we have to move beyond PDFs, and beyond a singular focus on results reports. We need to embrace data publishing as I'm sure John Wilbanks will be talking about at lunch. We need to publish study protocols as computable models, and publish results as computable data, so we can automate as much of the workflow as possible. We need to use text mining to extract meaning from prose, because there will always be, and should always be, prose for humans to read.An absolutely critical principle is that data cannot be in silos if we want to get the most out of evidence to improve health. We should pursue linked open data, again John will discuss, and the context for this data needs to be fully described. That is, we need metadata, or data about data. A simple example is a data point, let's say an odds ratio. The metadata, or context, for that odds ratio may include whether that odds ratio came from an RCT or an observational study. You can see that without good metadata, naked data can be downright dangerous. We also need ontologies. You can think of ontologies as standard computable ways of describing more complex abstractions, like what is a study question (so we can index and search on it), or my work on an Ontology of Clinical Research to describe study designs, or the Cochrane Ontology's standard description of the parts of a systematic review. I know this is all really abstract so I'll boil it down to a goal:
  39. The overall goal is to capture data in clearly described computable form that we can repurpose for multiple needs today, and for unknown needs tomorrow.
  40. Operationally for Cochrane Future Tech, a big challenge is to know what to have computers do, and what to leave humans do. Systematic review work is a mix of brain-numbingly tedious work mixed with highly skilled methodology work and clinical insight. The best technology solutions are going to be well-designed hybrid human-computer systems, which means seeking out and working with our colleagues in computer science, cognitive psychology and design t build the best hybrid systems. User interaction design is important. e.g., ExACT system.Part of this challenge is to support distributed collaborative knowledge work, tapping into crowds.
  41. Finally, there are many methodological frontiers for Cochrane Future. One is methods for generating more precise individual-level treatment estimates. Another is systematic review methods for complex interventions and continuous evaluation methods. Because the Big Data world will be full of messy, biased, confounded data, we need critical appraisal methods that can scale to the volume of evidence we will see. This will likely be semi-automated methods. I'm sure you can think of more.
  42. As I see it, these the points to keep in mind for the ambitious notion of a Human Evidence Project.First and foremost is to use technology not as an end to itself, but to use it to combine together human work and expertise, data and metadata, and computational methods to generate the most sound invidiual and population-level summary evidence for continuous learning.Mapping these basic principles to the workflow, we need ontologies of study questions and protocols to help with question framing, linked open data and text mining for assembling studies, we can say good riddance to abstraction if we publish in data and nanopublications, we need new statistical methods, and ontologies for diseases, care processes, decision making, etc. for effective D & I. Cochrane might not take on this whole challenge, but I can't see any other group besides Cochrane that can or should take the lead on this grand vision.
  43. In conclusion,